WallStSmart

AstraZeneca PLC (AZN)vsTurn Therapeutics Inc. Common Stock (TTRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.7Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

TTRX

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: -3.15
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+15.2%)

Margin of Safety

+15.2%

Fair Value

$195.81

Current Price

$166.08

$29.73 discount

UndervaluedFair: $195.81Overvalued

Intrinsic value data unavailable for TTRX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$257.57B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

TTRX0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AZN2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

TTRX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$453.69M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bull Case : TTRX

TTRX has a balanced fundamental profile.

Bear Case : AZN

The primary concerns for AZN are EPS Growth, Altman Z-Score.

Bear Case : TTRX

The primary concerns for TTRX are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 8.91 is elevated, increasing financial risk.

Key Dynamics to Monitor

AZN profiles as a mature stock while TTRX is a value play — different risk/reward profiles.

AZN is growing revenue faster at 6.4% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AZN scores higher overall (60/100 vs 17/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Turn Therapeutics Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Turn Therapeutics Inc., is a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company is headquartered in Westlake Village, California.

Want to dig deeper into these stocks?